|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM376926813 |
| 003 |
DE-627 |
| 005 |
20250306142510.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240902s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202409857
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1255.xml
|
| 035 |
|
|
|a (DE-627)NLM376926813
|
| 035 |
|
|
|a (NLM)39205511
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhang, Yulin
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Implantable Microneedle-Mediated Eradication of Postoperative Tumor Foci Mitigates Glioblastoma Relapse
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 03.10.2024
|
| 500 |
|
|
|a Date Revised 03.10.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Glioblastoma multiforme (GBM) remains incurable despite multimodal treatments after surgical debulking. Almost all patients with GBM relapse within a narrow margin (2-3 cm) of the initial resected lesion due to the unreachable residual cancerous cells. Here, a completely biodegradable microneedle for surgical cavity delivery glioblastoma-associated macrophages (GAMs)-activating immune nano-stimulator that mitigates glioblastoma relapse is reported. The residual tumor lesion-directed biocompatible microneedle releases the nano-stimulator and toll-like receptor 9 agonist in a controlled manner until the microneedles completely degrade over 1 week, efferently induce in situ phonotypic shifting of GAMs from anti- to pro-inflammatory and the tumor recurrence is obviously inhibited. The implantable microneedles offer a significant improvement over conventional transdermal ones, as they are 100% degradable, ensuring safe application within surgical cavities. It is also revealed that the T cells are recruited to the tumor niche as the GAMs initiate anti-tumor response and eradicate residual GBM cells. Taken together, this work provides a potential strategy for immunomodulating the postoperative tumor niche to mitigate tumor relapse in GBM patients, which may have broad applications in other malignancies with surgical intervention
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a bio‐degradable microneedle
|
| 650 |
|
4 |
|a glioblastoma
|
| 650 |
|
4 |
|a tumor‐associated macrophage
|
| 650 |
|
7 |
|a Toll-Like Receptor 9
|2 NLM
|
| 700 |
1 |
|
|a Fang, Zezheng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Zejuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xi, Kaiyan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Yi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Dawang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Feng, Fan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Geng, Humin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Minglu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lou, Jingzhao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Chen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Yanmin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Zimei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Feng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jiang, Xinyi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ni, Shilei
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 40 vom: 15. Okt., Seite e2409857
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:40
|g day:15
|g month:10
|g pages:e2409857
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202409857
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 40
|b 15
|c 10
|h e2409857
|